Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495). (April 2018) - Brenneis, C.; Serruys, B.; Van Belle, T.; Poelmans, S.; Kleinschmidt-Doerr, K.; Guehring, H.; Michaelis, M.; Lindemann, S.